A Phase 1 Trial of a Single ProHema CB Product (Ex Vivo Modulated Human Cord Blood Cells) Following Myeloablative Conditioning for Pediatric Patients With Hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2017
At a glance
- Drugs FT 1050 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Acronyms PROMPT
- Sponsors Fate Therapeutics
- 11 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.
- 11 Apr 2016 Status changed from recruiting to discontinued.
- 07 Feb 2015 New trial record